Document:

EX-10.2

 Exhibit 10.2 

INTELLECTUAL PROPERTY SECURITY AGREEMENT 

This Intellectual Property Security Agreement (this “IP Agreement”) is made August 28, 2013 by and among Bioject Medical
Technologies Inc. (the “Company”) and its wholly owned subsidiary Bioject Inc. (the “Subsidiary”), each an Oregon corporation, and each with offices at, 7180 SW Sandburg Street, Tigard, Oregon 97223 (collectively, the
“Grantors”), and Mark Logomasini, the holders of the Company Senior’s Secured Bridge Promissory Note aggregating $120,000 dated August 28, 2013 (the “Note”) and with the address also set forth on the signature page
hereto (the “Noteholder”). 
 RECITALS 

The Noteholder has agreed to make a secured bridge loan to the Company, evidenced by the Note. The Note provides that the Note is secured by all the
intellectual property of the Grantors. Accordingly, the Grantors will grant to the Noteholder a security interest in all of Grantors’ right title and interest, whether presently existing or hereafter acquired in, to and under all of the
Collateral (as defined therein). 
 NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged and
intending to be legally bound, as collateral security for the prompt and complete payment when due of the Note, Grantors hereby represent, warrant, covenant and agree as follows: 

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantors’
present or future obligations under the Note, Grantors hereby grants a security interest in all of Grantors’ right, title and interest in, to and under its registered and unregistered Collateral (all of which shall collectively be called the
“Collateral”), including, without limitation, the following: 
 (a) All patents, patent applications and like
protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on
EXHIBIT A attached hereto (collectively, the “Patents”); 
 (b) Any trademark and service
mark rights, slogans, trade dress, and trade names, trade styles, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantors connected with and
symbolized by such trademarks, including without limitation those set forth on EXHIBIT A attached hereto (collectively, the “Trademarks”); 

(c) Any and all trade secret rights, including any rights to unpatented inventions, know-how, operating manuals, license rights
and agreements, and confidential information, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held; 

(d) All licenses or other rights to use any of the Patents or Trademarks, and all license fees and royalties arising from such
use to the extent permitted by such license or rights; 
 (e) All amendments, extensions, renewals and extensions of any
of the Trademarks, Patents; and 
 (f) All proceeds and products of the foregoing, including without limitation all
payments under insurance or any indemnity or warranty payable in respect of any of the foregoing. 

  
 1 

 2. Covenants and Warranties. Grantors represents, warrants, covenants and agrees as
follows: 
 (a) Grantors are the sole owners of the Collateral, except for licenses granted by Grantors to their
customers in the ordinary course of business.
 (b) Performance of this IP Agreement does not conflict with or result in
a breach of any material agreement to which Grantors are bound. 
 (c) During the term of this IP Agreement, Grantors
will not transfer or otherwise encumber any interest in the Collateral, except for licenses granted by Grantors in the ordinary course of business or as otherwise permitted in this IP Agreement; 

(d) To their knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged
invalid or unenforceable, in whole or in part, and no claim has been made in writing that any part of the Collateral violates the rights of any third party;

(e) Grantors shall advise Noteholder of any subsequent ownership right of the Grantors in or to any Trademark or Patent
specified in this IP Agreement; 
 (f) Grantors shall (i) protect, defend and maintain the validity and
enforceability of the Trademarks and Patents material to Grantors’ business, (ii) use reasonable commercial efforts to detect infringements of the Trademarks and Patents, and promptly advise Noteholder in writing of material infringements
detected and (iii) not allow any Trademarks and Patents, material to Grantors’ business to be abandoned, forfeited or dedicated to the public without the written consent of Noteholder, which shall not be unreasonably withheld, unless
Grantors determine that reasonable business practices suggest that abandonment is appropriate. 
 (g) Grantors shall
take such further actions as Noteholder may reasonably request from time to time to perfect or continue the perfection of Noteholder’s interest in the Collateral; 

(h) This IP Agreement creates, and in the case of after acquired Collateral this IP Agreement will create, at the time
Grantors first has rights in such after acquired Collateral and Noteholder has taken all actions required for perfection, in favor of Noteholder, a valid and perfected first priority security interest and collateral assignment in the Collateral in
the United States securing the payment and performance of the obligations evidenced by the Note; 
 (i) To its
knowledge, except for, and upon, the filing of UCC financing statements, or other notice filings or notations in appropriate filing offices, if necessary to perfect the security interests created hereunder, no authorization, approval or other action
by, and no notice to or filing with, any U.S. governmental authority or U.S. regulatory body is required either (a) for the grant by Grantors of the security interest granted hereby, or for the execution, delivery or performance of this IP
Agreement by Grantors in the U.S. or (b) for the perfection in the United States or the exercise by Noteholder of its rights and remedies thereunder; 

(j) All information heretofore, herein or hereafter supplied to Noteholder by or on behalf of Grantors with respect to the
Collateral is true and correct in all material respects. 
 (k) Grantors shall not enter into any agreement that would
materially impair or conflict with Grantors’ obligations hereunder without Noteholder’s prior written consent, which consent shall not be unreasonably withheld. Except as permitted under the Note, Grantors shall not permit the inclusion in
any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantors’ rights and interest in any property included within the definition of the Collateral
acquired under such contracts. 
 4. Noteholder’s Rights. Noteholder shall have the right, but not the obligation, to take,
at Grantors’ sole expense, any actions that Grantors is required under this IP Agreement to take but which Grantors fails to timely take, after fifteen (15) days’ notice to Grantors. Grantors shall reimburse and indemnify Noteholder
for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this section 4. 

  
 2 

 5. Further Assurances; Attorney in Fact. 

(a) On a continuing basis, Grantors will, upon reasonable request by Noteholder, subject to any prior licenses, encumbrances and
restrictions and prospective licenses, make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and
collateral agreements and filings with the United States Patent and Trademarks Office and the Register of Copyrights, and take all such action as may reasonably be requested by Noteholder, to perfect Noteholder’s security interest in all
Patents and Trademarks and otherwise to carry out the intent and purposes of this IP Agreement, or for assuring and confirming to Noteholder the grant or perfection of a security interest in all Collateral, provided that Grantors shall not be
required to register any Collateral that Grantors determines, consistent with reasonable business practice, need not be registered. 

(b) Grantors appoints Noteholder as Grantor’s attorney-in-fact, with full authority in the place and stead of Grantors and in the
name of Grantors, Noteholder or otherwise, from time to time in Noteholder’s discretion, upon Grantor’s failure or inability to do so, to take any action and to execute any instrument which Noteholder may deem reasonably necessary or
advisable to accomplish the purposes of this IP Agreement, including: 
 (i) To modify, in its sole discretion, this IP
Agreement without first obtaining Grantor’s approval of or signature to such modification by amending Exhibit A, as appropriate, to include reference to any right, title or interest in any Patents or Trademarks acquired by Grantors after
the execution hereof or to delete any reference to any right, title or interest in any Patents or Trademarks Works in which Grantors no longer have or claim any right, title or interest; and 

(ii) To file, in its sole discretion, one or more financing or continuation statements and amendments thereto, or other
notice filings or notations in appropriate filing offices, relative to any of the Collateral, without notice to Grantors, with all appropriate jurisdictions, as Noteholder deems appropriate, in order to perfect or protect Noteholder’s interest
in the Collateral. 
 6. Events of Default. The occurrence of an Event of Default under the Note shall constitute an Event of
Default under this IP Agreement. 
 7. Remedies. Upon the occurrence and during the continuance of an Event of Default,
Noteholder shall have the right to exercise all the remedies of a secured party under the Oregon Uniform Commercial Code, including without limitation the right to require Grantors to assemble the Collateral and any tangible property in which
Noteholder have a security interest and to make it available to Noteholder at a place designated by Noteholder. Noteholder shall have a nonexclusive, royalty free license to use the Patents and Trademarks to the extent reasonably necessary to permit
Noteholder to exercise their rights and remedies upon the occurrence and during the continuance of an Event of Default. Grantors will pay any expenses (including reasonable attorney’s fees) incurred by Noteholder in connection with the exercise
of any of Noteholder’s rights hereunder, including without limitation any expense incurred in disposing of the Collateral in accordance with the terms hereof. All of Noteholder’s rights and remedies with respect to the Collateral shall be
cumulative. 
 8. Indemnity. Grantors agrees to defend, indemnify and hold harmless Noteholder and its agents (each an
“Indemnified Person”) against: (a) all obligations, demands, claims, and liabilities (collectively, “Claims”) claimed or asserted by any other party in connection with the transactions contemplated by this IP Agreement, and
(b) all losses or expenses in any way suffered, incurred, or paid by Noteholder as a result of or in any way arising out of, following or consequential to transactions between Noteholder and Grantors, under this IP Agreement (including without
limitation, reasonable attorney’s fees and reasonable expenses), except for Claims and/or losses arising from or out of an Indemnified Person’s gross negligence or willful misconduct. 

9. Termination. At such time as Grantors shall completely repay the Note and any other obligations under the Note, secured
hereunder, Noteholder shall execute and deliver to Grantors all releases, terminations, and other instruments as may be necessary or proper to release the security interest hereunder. 

  
 3 

 10. Course of Dealing. No course of dealing, nor any failure to exercise, nor any
delay in exercising any right, power or privilege hereunder shall operate as a waiver thereof. 
 11. Amendments. This IP
Agreement may be amended only by a written instrument signed by both parties hereto. 
 12. Counterparts. This IP Agreement may
be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument. 

13. Law and Jurisdiction. This IP Agreement shall be governed by and construed in accordance with the laws of the State of Oregon.
GRANTORS ACCEPT FOR THEMSELF AND IN CONNECTION WITH THEIR PROPERTIES, UNCONDITIONALLY, THE NON-EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT OF COMPETENT JURISDICTION IN THE STATE OR OREGON IN ANY ACTION, SUIT, OR PROCEEDING OF ANY KIND,
AGAINST IT WHICH ARISES OUT OF OR BY REASON OF THIS IP AGREEMENT; PROVIDED, HOWEVER, THAT IF FOR ANY REASON NOTEHOLDER CANNOT AVAIL THEMSELVES OF THE COURTS OF THE STATE OF OREGON, GRANTORS ACCEPTS JURISDICTION OF THE COURTS AND VENUE IN ORANGE
COUNTY, CALIFORNIA. NOTWITHSTANDING THE FOREGOING, THE NOTEHOLDER SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST THE GRANTORS OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH THE NOTEHOLDER DEEMS NECESSARY OR APPROPRIATE
IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE NOTEHOLDER’ RIGHTS AGAINST THE GRANTORS OR THEIR PROPERTY. 

GRANTORS AND NOTEHOLDER EACH HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF
ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS. EACH PARTY RECOGNIZES AND AGREES THAT THE FOREGOING WAIVER
CONSTITUTES A MATERIAL INDUCEMENT FOR IT TO ENTER INTO THIS AGREEMENT. EACH PARTY REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING
CONSULTATION WITH LEGAL COUNSEL. 
 14. Confidentiality. In handling any confidential information, Noteholder shall exercise the
same degree of care that they exercise for their own proprietary information, but disclosure of information may be made: (i) to Noteholder or affiliates in connection with their present or prospective business relations with Grantors;
(ii) to prospective transferees or purchasers of any interest in the Note (provided, however, Noteholder shall use commercially reasonable efforts to obtain such prospective transferee’s or purchaser’s agreement to the terms of
this

  
 4 

 
provision); (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Noteholder’s examination or audit; and (v) as Noteholder
considers appropriate in exercising remedies under this Agreement. Confidential information does not include information that either: (a) is in the public domain or in Noteholder’ possession when disclosed to Noteholder, or becomes part of
the public domain after disclosure to Noteholder through no fault of Noteholder; or (b) is disclosed to Noteholder by a third party, if Noteholder reasonably does not know that the third party is prohibited from disclosing the information. 

Agreed, as of the date first set forth above: 
 Grantors:

 Bioject Medical Technologies Inc. 
  

			
	By: 	 	/s/ Christine M. Farrell
	Name: Christine M. Farrell
	Title: Vice President of finance

 Bioject Inc. 
  

			
	By: 	 	/s/ Christine M. Farrell
	Name: Christine M. Farrell
	Title: Vice President of Finance

 Noteholder: 
  

	
	/s/ Mark Logomasini
	Mark Logomasini

  
 5 

 Exhibit A 

SCHEDULE A 
 Bioject
Inc. 
 Trademark Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
			
	 BIOJECT & Design
	  	2095147	  	9/9/1997
			
	 BIOJECT ZETAJET
	  	4220613	  	10/9/2012
			
	 BIOJECTOR
	  	2095148	  	9/9/1997
			
	 IJECT
	  	2810887	  	2/3/2004
			
	 VITAJET
	  	1838619	  	6/7/1994
			
	 Foreign Trademarks:
	  		  	
			
	 B-2000
	  	3300833	  	12/14/2005
			
	 BIOJECT
	  	3301088	  	1/14/2007
			
	 BIOJECT
	  	05925 2003	  	8/9/2009
			
	 BIOJECT & Design
	  	200508684	  	2/23/2006
			
	 BIOJECT ZETAJET
	  	9701257	  	8/21/2012
			
	 BIOJECT ZETAJET
	  	9136094	  	11/8/2010
			
	 BIOJECT ZETAJET
	  	5477139	  	3/9/2012
			
	 BIOJECT and Design
	  	526097	  	3/30/2000
			
	 BIOJECT and Design
	  	497123	  	3/9/1999
			
	 BIOJECT and Design
	  	4172641	  	7/31/1998
			
	 BIOJECTOR & Design
	  	378650	  	1/25/1991
			
	 PETJET
	  	4310215	  	2/1/2006
			
	 VET JET
	  	4310207	  	2/22/2006

  
 6 

 SCHEDULE B 

Bioject Inc. 
 Patent
Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
	 US Patents:
	  		  	
			
	 Ampule Filling Device
	  	5,649,912	  	7/22/1997
			
	 Ampule for Needleless Injection
	  	5,503,627	  	4/2/1996
			
	 Disposable Needle-free Injection Apparatus and Method
	  	6,607,510	  	8/19/2003
			
	 Disposable Needle-Free Injection Apparatus and Method
	  	6,471,669	  	10/29/2002
			
	 Disposable Needle-Free Injection Apparatus and Method
	  	6,641,554	  	11/4/2003
			
	 Drug Cartridge Assembly and Method of Manufacture
	  	6,883,222	  	4/26/2005
			
	 Drug Vial Mixing and Transfer Device
	  	5,466,220	  	11/14/1995
			
	 Durable Hypodermic Jet Injector Apparatus and Method
	  	6,752,781	  	6/22/2004
			
	 Durable Needle-less Jet Injector Apparatus and Method
	  	6,648,850	  	11/18/2003
			
	 Electrically Powered Jet Injector
	  	5,505,697	  	4/9/1996
			
	 Ergonomic Needle-less Jet Injection Apparatus and Method
	  	6,572,581	  	6/3/2003
			
	 High Workload Needle-Free Injection System
	  	7,156,823	  	1/2/2007
			
	 Injection Apparatus
	  	D399,951	  	10/20/1998
			
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
	  	6,319,224	  	11/20/2001
			
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
	  	6,752,780	  	6/22/2004
			
	 Jet Injector Apparatus and Method
	  	6,585,685	  	7/1/2003
			
	 Medication Vial/Syringe Liquid-Transfer Apparatus
	  	5,893,397	  	4/13/1999
			
	 Method for Manufacturing an Ampule
	  	5,312,577	  	5/17/1994

  
 7 

					
			
	 Needle-Free Injection Devices and Drug Delivery Systems Therefor
	  	7,744,563	  	6/29/2010
			
	 Needle-Free Injection System
	  	7,717,874	  	5/18/2010
			
	 Needle-Free Injection System
	  	6,676,630	  	1/13/2004
			
	 Needle-Free Injection System
	  	7,238,167	  	7/3/2007
			
	 Needle-Free Injector and Process for Providing Serial Injections
	  	7,942,845	  	5/17/2011
			
	 Needleless Hypodermic Injection Device
	  	5,383,851	  	1/24/1995
			
	 Needleless Hypodermic Injection Device
	  	5,312,335	  	5/17/1994
			
	 Needleless Hypodermic Injection Methods and Device
	  	5,399,163	  	3/21/1995
			
	 Needleless Hypodermic Injection Methods and Device
	  	5,520,639	  	5/28/1996
			
	 Needle-less Injection System
	  	6,506,177	  	1/14/2003
			
	 Needleless Syringe with Prefilled Cartridge
	  	6,132,395	  	10/17/2000
			
	 Needleless Syringe with Prefilled Cartridge
	  	6,383,168	  	5/7/2002
			
	 NGAS Powered Self-Resetting Needle-Less Hypodermic Jet Injection Apparatus and Method
	  	6,096,002	  	8/1/2000
			
	 Simplified Disposable Needle-Free Injection Apparatus and Method
	  	6,645,170	  	11/11/2003
			
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
	  	6,264,629	  	7/24/2001
			
	 Single-Use Needle-Less Hypodermic Jet Injection Apparatus and Method
	  	6,783,509	  	8/31/2004
			
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
	  	6,689,093	  	2/10/2004
			
	 Spring Powered Needle-Free Injection System
	  	7,442,182	  	10/28/2008
			
	 Triggering Mechanism for a Needle-Free Injector
	  	7,547,293	  	6/16/2009
			
	 Foreign Patents:
	  		  	
			
	 Drug Cartridge Assembly and Method of Manufacture
	  	4816/BE/2011	  	3/11/2011
			
	 Drug Cartridge Assembly and Method of Manufacture
	  	1551476	  	8/28/2003
			
	 Drug Cartridge Assembly and Method of Manufacture
	  	1551476	  	8/28/2003

  
 8 

					
			
	 Drug Cartridge Assembly and Method of Manufacture
	  	1551476	  	3/11/2011
			
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
	  	1,229,950	  	5/18/2005
			
	 Intradermal Injection System for Injecting DNA-Based Injectables into Humans
	  	ZL 00813342.5	  	11/2/2005
			
	 Medication Vial/Syringe Liquid-Transfer Apparatus
	  	3916713	  	2/16/2007
			
	 Medication Vial/Syringe Liquid-Transfer Apparatus
	  	783879	  	5/21/2003
			
	 Medication Vial/Syringe Liquid-Transfer Apparatus
	  	2,192,623	  	6/27/2000
			
	 Needleless hypodermic Injection Methods and Device
	  	3633615	  	1/7/2005
			
	 Needleless hypodermic Injection Methods and Device
	  	0651663	  	12/01/1999
			
	 Needleless hypodermic Injection Methods and Device
	  	676490	  	7/10/1997
			
	 Needleless hypodermic Injection Methods and Device
	  	2,140,772	  	7/11/2006
			
	 Needleless Syringe with Prefilled Cartridge
	  	2353948	  	5/20/2008
			
	 Needleless syringe with prefilled cartridge
	  	HK1055912	  	11/18/2005
			
	 Needleless Syringe with Prefilled Cartridge
	  	2,407,056	  	11/18/2008
			
	 Needleless Syringe with Prefilled Cartridge
	  	4709461	  	3/25/2011
			
	 Needleless Syringe with Prefilled Cartridge
	  	ZL 01807774.9	  	6/22/2005
			
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
	  	229947	  	8/12/2005
			
	 Single-use Needle-less Hypodermic Jet Injection Apparatus and Method
	  	1202762	  	7/6/2011

  
 9 

 Bioject Medical Technologies, Inc. 

Trademark Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
	 USA Trademarks:
	  		  	
	 BIOJECT®
	  	2440716	  	4/3/2001

 Patent Schedule 
  

					
	 Description
	  	Registration/
Application
Number	  	Registration/
Application
Date
	 USA Patents:
	  		  	
	 Multiple use needle-less hypodermic injection device for individual users
	  	5782802	  	7/21/1998

  
 10EX-10.1

 Exhibit 10.1 
 SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 
 This
Supplemental Executive Retirement Plan (the “Agreement”), by and between West View Savings Bank, located in Pittsburgh, Pennsylvania (hereinafter referred to as the “Employer”), and David Bursic (hereinafter referred to as the
“Executive”), effective as of the 1st day of
September 2013, formalizes the agreements and understanding between the Employer and the Executive. The Employer is the wholly owned subsidiary of WVS Financial Corp. (the “Corporation”). 

WITNESSETH: 
 WHEREAS, the Executive is employed by the Employer; 
 WHEREAS, the Employer
recognizes the valuable services the Executive has performed for the Employer and wishes to encourage the Executive’s continued employment and to provide the Executive with additional incentive to achieve corporate objectives; 

WHEREAS, the Employer wishes to provide the terms and conditions upon which the Employer shall pay additional retirement benefits to the
Executive; 
 WHEREAS, the Employer and the Executive intend this Agreement shall at all times be administered and interpreted
in compliance with Code Section 409A; 
 WHEREAS, the Employer intends that this Agreement shall at all times be
administered and interpreted in such a manner as to constitute an unfunded nonqualified deferred compensation arrangement, maintained primarily to provide supplemental retirement benefits for the Executive, a member of a select group of management
or highly compensated employee of the Employer; and 
 WHEREAS, the Employer intends that this Agreement shall at all times be
characterized as a “top hat” plan of deferred compensation and that this Agreement shall at all times satisfy Code Section 409A, with the provisions of this Agreement to be construed to effectuate the foregoing intentions. 

NOW THEREFORE, in consideration of the premises and of the mutual promises herein contained, the Employer and the Executive agree as
follows: 
 ARTICLE 1 
 DEFINITIONS 
 For the purpose of this Agreement, the following phrases or
terms shall have the indicated meanings: 
 1.1 “Account Balance” means the amount shown on Schedule A under
the “Account Balance” Column. 

 1.2 “Administrator” means the Board or its designee. 

1.3 “Affiliate” means any business entity with whom the Employer would be considered a single employer under Sections
414(b) and 414(c) of the Code. Such term shall be interpreted in a manner consistent with the definition of “service recipient” contained in Code Section 409A. 
 1.4 “Beneficiary” means the person or persons designated in writing by the Executive to receive benefits hereunder in the event of the Executive’s death. 

1.5 “Board” means the Board of Directors of the Employer. 

1.6 “Cause” means the termination of the Executive’s employment because of personal dishonesty, incompetence,
willful misconduct, breach of fiduciary duty involving personal profit, intentional failure to perform stated duties, willful violation of any law, rule or regulation (other than traffic violations or similar offenses) or final cease-and-desist
order or material breach of any provision of the Agreement. For purposes of this paragraph, no act or failure to act on the Executive’s part shall be considered “willful” unless done, or omitted to be done, by the Executive not in
good faith and without reasonable belief that the Executive’s action or omission was in the best interest of the Employer. 

1.7 “Change in Control” means a change in the ownership or effective control of the Employer or the Corporation, or in
the ownership of a substantial portion of the assets of the Employer or the Corporation, in each case as such change is defined in Code Section 409A and the regulations thereunder. 

1.8 “Claimant” means a person who believes that he or she is being denied a benefit to which he or she is entitled
hereunder. 
 1.9 “Code” means the Internal Revenue Code of 1986, as amended. 

1.10 “Disability” means a condition of the Executive whereby the Executive either: (i) is unable to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, or (ii) is, by reason of
any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three
months under an accident and health plan covering employees of the Employer. The Administrator will determine whether the Executive has incurred a Disability based on its own good faith determination and may require the Executive to submit to
reasonable physical and mental examinations for this purpose. The Executive will also be deemed to have incurred a Disability if determined to be totally disabled by the Social Security Administration or in

  
 2 

 
accordance with a disability insurance program, provided that the definition of disability applied under such disability insurance program complies with the initial sentence of this Section.

 1.11 “Distribution Rate” means a 20 year A rated financial institution index such as the Bloomberg IGUUFA20
Index or another such rate agreed upon by the Employer and the Executive. The measurement date shall be the month-end before payments commence and each June 30 thereafter. The rate established at each June 30 will be credited for the next
twelve (12) months. 
 1.12 “Early Termination” means Separation from Service before Normal Retirement Age
except when such Separation from Service occurs within twenty-four (24) months following a Change in Control or due to termination for Cause. 
 1.13 “Effective Date” means September 1, 2013. 
 1.14
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 
 1.15 “Normal
Retirement Age” means the date the Executive attains age sixty-five (65). 
 1.16 “Plan Year” means
each twelve (12) month period commencing on July 1 and ending on June 30 of each year. The initial Plan Year shall commence on the Effective Date and end on the following June 30. 

1.17 “Schedule A” means the schedule attached hereto and made a part hereof. Schedule A shall be updated upon a change
to any of the benefits described in Article 2 hereof. 
 1.18 “Separation from Service” means a termination of
the Executive’s employment with the Employer and its Affiliates for reasons other than death or Disability. A Separation from Service may occur as of a specified date for purposes of the Agreement even if the Executive continues to provide some
services for the Employer or its Affiliates after that date, provided that the facts and circumstances indicate that the Employer and the Executive reasonably anticipated at that date that either no further services would be performed after that
date, or that the level of bona fide services the Executive would perform after such date (whether as an employee or as an independent contractor) would permanently decrease to no more than twenty percent (20%) of the average level of bona fide
services performed (whether as an employee or as an independent contractor) over the immediately preceding thirty-six (36) month period (or the full period during which the Executive performed services for the Employer, if that is less than
thirty-six (36) months). A Separation from Service will not be deemed to have occurred while the Executive is on military leave, sick leave, or other bona fide leave of absence if the period of such leave does not exceed six (6) months or,
if longer, the period for which a statute or contract provides the Executive with the right to reemployment with the Employer. If the Executive’s leave exceeds six (6) months but the Executive is not entitled to reemployment

  
 3 

 
under a statute or contract, the Executive shall be deemed to incur a Separation from Service on the first day following the expiration of such six (6) month period. In determining whether a
Separation from Service occurs, the Administrator shall take into account, among other things, the facts and circumstances required to be considered by Treasury Regulation §1.409A-1(h), including the definitions of “service recipient”
and “employer” set forth in Treasury Regulation §1.409A-1(h)(3). The Administrator shall have full and final authority to determine conclusively whether a Separation from Service occurs, and the date of such Separation from Service.

 1.19 “Specified Employee” means an individual who at the time of Separation from Service satisfies the
definition of a “key employee” of the Employer as such term is defined in Code §416(i)(1)(A)(i), (ii) or (iii) (applied in accordance with the regulations thereunder and disregarding Code §416(i)(5)), provided that the
stock of the Employer is publicly traded on an established securities market or otherwise, as defined in Code §1.897-1(m). If the Executive is a key employee at any time during the twelve (12) months ending on December 31, the
Executive is a Specified Employee for the twelve (12) month period commencing on the first day of the following April. 

ARTICLE 2 

PAYMENT OF BENEFITS 
 2.1 Normal Retirement Benefit. Upon Separation from Service on or after Normal Retirement Age, the Employer shall pay the Executive the benefit shown in the Account Balance column on Schedule A for
the Plan Year ending immediately prior to Separation from Service. Additionally, the benefit amount shall be increased by a pro-rated amount relative to the Executive’s service during the partial Plan Year in which Separation from Service takes
place. The benefit will be paid in sixty (60) monthly installments commencing the month following Separation from Service (subject Section 2.9), with interest credited on the unpaid balance at an annual rate equal to the Distribution Rate,
compounded monthly. Notwithstanding the foregoing, if Separation from Service occurs after the Executive reaches Normal Retirement Age, for each full month between Normal Retirement Age and Separation from Service, up to a maximum of sixty
(60) months, the Employer shall increase the Account Balance by .2466%. The Employer may further increase the Normal Retirement Benefit under this Section 2.1 at the sole and absolute discretion of the Board. Any such discretionary
increase shall require the recalculation of all the amounts on Schedule A attached hereto. Each time the Distribution Rate changes, the outstanding balance to be paid to the Executive shall be re-amortized over the remaining distribution period.

 2.2 Early Termination Benefit. If Early Termination occurs, the Employer shall pay the Executive the benefit shown in
the Early Termination Vested Account Balance column on Schedule A for the Plan Year ending immediately prior to Separation from Service. Additionally, the benefit amount shall be increased by a pro-rated amount relative to the Executive’s
service during the partial Plan Year in which Separation from Service takes place. The benefit will be paid in sixty (60) monthly installments commencing the month following Separation from Service (subject to Section 2.9), with interest
credited on 

  
 4 

 
the unpaid balance at an annual rate equal to the Distribution Rate, compounded monthly. Each time the Distribution Rate changes, the outstanding balance to be paid to the Executive shall be
re-amortized over the remaining distribution period. 
 2.3 Disability Benefit. In the event the Executive suffers a
Disability prior to Normal Retirement Age, the Employer shall pay the Executive the benefit shown in the Disability Vested Account Balance column on Schedule A for the Plan Year ending immediately prior to Disability. Additionally, the benefit
amount shall be increased by a pro-rated amount relative to the Executive’s service during the partial Plan Year in which Disability takes place. The benefit will be paid in sixty (60) monthly installments commencing the month following
Disability with interest credited on the unpaid balance at an annual rate equal to the Distribution Rate, compounded monthly. Each time the Distribution Rate changes, the outstanding balance to be paid to the Executive shall be re-amortized over the
remaining distribution period. 
 2.4 Change in Control Benefit. If a Change in Control occurs, followed within
twenty-four (24) months by Separation from Service prior to Normal Retirement Age, the Employer shall pay the Executive the annual benefit shown in the Change in Control Annual Benefit column on Schedule A for the Plan Year ending immediately
prior to Separation from Service. Additionally, the benefit amount shall be increased by a pro-rated amount relative to the Executive’s service during the partial Plan Year in which Separation from Service takes place. The annual benefit shall
be paid in equal monthly installments for five (5) years, commencing the month following Separation from Service (subject to Section 2.9). 
 2.5 Death Prior to Commencement of Benefit Payments. In the event the Executive dies prior to Separation from Service, the Employer shall pay the Beneficiary the amount shown in the Pre-retirement
Death Benefit column on Schedule A for the Plan Year ending immediately prior to the Executive’s death. Additionally, the benefit amount shall be increased by a pro-rated amount relative to the Executive’s service during the partial Plan
Year in which the Executive’s death takes place. The benefit will be paid in a lump sum within ninety (90) days following the Executive’s death, with the precise payment date determined by the Employer in its sole discretion.

 2.6 Death Subsequent to Commencement of Benefit Payments. In the event the Executive dies while receiving payments,
but prior to receiving all payments due and owing hereunder, the Employer shall pay the Beneficiary the present value of the remaining payments hereunder, calculated using the Distribution Rate, in a lump sum within ninety (90) days following
the Executive’s death, with the precise payment date determined by the Employer in its sole discretion. 
 2.7
Termination for Cause. If the Employer terminates the Executive’s employment for Cause, then the Executive shall not be entitled to any benefits under the terms of this Agreement. 

  
 5 

 2.8 Restriction on Commencement of Distributions. Notwithstanding any provision
of this Agreement to the contrary, if the Executive is considered a Specified Employee at the time of Separation from Service, the provisions of this Section shall govern all distributions hereunder resulting from the Separation from Service.
Distributions which would otherwise be made to the Executive due to Separation from Service shall not be made during the first six (6) months following Separation from Service. Rather, any distributions which would otherwise be paid to the
Executive during such period shall be accumulated and paid to the Executive in a lump sum on the first day of the seventh month following Separation from Service or, if earlier, upon the Executive’s death. All subsequent distributions shall be
paid as they would have been paid had this Section not applied. 
 2.9 Acceleration of Payments. Except as specifically
permitted herein, no acceleration of the time or schedule of any payment may be made hereunder. Notwithstanding the foregoing, payments may be accelerated, in accordance with the provisions of Treasury Regulation §1.409A-3(j)(4) in the
following circumstances: (i) as a result of certain domestic relations orders; (ii) in compliance with ethics laws or conflicts of interest laws; (iii) in limited cashouts (but not in excess of the limit under Code
§402(g)(1)(B)); (iv) to pay employment-related taxes; or (v) to pay any taxes that may become due at any time that the Agreement fails to meet the requirements of Code Section 409A. 

2.10 Delays in Payment by Employer. A payment may be delayed to a date after the designated payment date under any of the
circumstances described below, and the provision will not fail to meet the requirements of establishing a permissible payment event, provided that the delay in payment complies with all of the requirements of Treasury Regulation
§1.409A-2(b)(7). The delay in the payment will not constitute a subsequent deferral election, so long as the Employer treats all payments to similarly situated service providers on a reasonably consistent basis. 

(a) Payments subject to Code Section 162(m). If the Employer reasonably anticipates that
the Employer’s deduction with respect to any distribution under this Agreement would be limited or eliminated by application of Code Section 162(m), then to the extent deemed necessary by the Employer to ensure that the entire amount of
any distribution from this Agreement is deductible, the Employer may delay payment of any amount that would otherwise be distributed under this Agreement. The delayed amounts shall be distributed to the Executive (or the Beneficiary in the event of
the Executive’s death) either (i) during the Executive’s first taxable year in which the Employer reasonably anticipates, or should reasonably anticipate, that the deduction of the payment of the amount will not be limited or
eliminated by application of Code Section 162(m), or (ii) during the period beginning with the date of the Executive’s Separation from Service and ending on the later of the last day of the year in which the Separation from Service
occurs or the 15th day of the third month following the
Separation from Service, subject to further delay in accordance with Treasury Regulation §1.409A-2(b)(7) if the Executive is a Specified Employee at the time of the Separation from Service. 

  
 6 

 (b) Payments that would violate federal securities laws or other
applicable law. A payment may be delayed where the Employer reasonably anticipates that the making of the payment will violate federal securities laws or other applicable law, provided that the payment is made at the earliest date at which the
Employer reasonably anticipates that the making of the payment will not cause such violation. The making of a payment that would cause inclusion in gross income or the application of any penalty provision or other provision of the Code is not
treated as a violation of law. 
 (c) Solvency. Notwithstanding the above, a payment may be delayed where
the payment would jeopardize the ability of the Employer to continue as a going concern, provided that the payment is made during the first calendar year in which the making of the payment would not have such effect. 

2.11 Treatment of Payment as Made on Designated Payment Date. Solely for purposes of determining compliance
with Code Section 409A, any payment under this Agreement made after the required payment date shall be deemed made on the required payment date, provided that such payment is made by the latest of: (i) the end of the calendar year in which
the payment is due; (ii) the 15th day of the third
calendar month following the payment due date; (iii) if the Employer cannot calculate the payment amount on account of administrative impracticality due to events beyond the control of the Executive (or the Executive’s beneficiary), the
end of the first calendar year in which payment calculation is administratively practicable; and (iv) if the Employer does not have sufficient funds to make the payment without jeopardizing the Employer’s ability to continue as a going
concern, in the first calendar year in which the Employer’s funds are sufficient to make the payment, and provided in each case that all of the requirements of Treasury Regulation §1.409A-3(d) are satisfied. 

2.12 Facility of Payment. If a distribution is to be made to a minor, or to a person who is otherwise incompetent, then the
Administrator may make such distribution: (i) to the legal guardian, or if none, to a parent of a minor payee with whom the payee maintains his or her residence; or (ii) to the conservator or administrator or, if none, to the person having
custody of an incompetent payee. Any such distribution shall fully discharge the Employer and the Administrator from further liability on account thereof. 
 2.13 Changes in Form of Timing of Benefit Payments. The Employer and the Executive may, subject to the terms hereof, amend this Agreement to delay the timing or change the form of payments. Any
such amendments shall comply with all of the requirements of Treasury Regulation §1.409A-2(b), including the following: 
 (a) the amendment must take effect not less than twelve (12) months after the amendment is made; 
 (b) the amendment must, for benefits distributable due solely to the arrival of a specified date, or on account of a Separation from Service or a Change in Control, delay the commencement of distributions
for a minimum of five (5) years from the date the first distribution would otherwise have been paid; 

  
 7 

 (c) the amendment must, for benefits distributable due solely to the arrival
of a specified date, be made not less than twelve (12) months before distribution is scheduled to begin; and 
 (d) the amendment may not accelerate the time or schedule of any distribution. 

ARTICLE 3 

BENEFICIARIES 
 3.1 Designation of Beneficiaries. The Executive may designate any person to receive any benefits payable under the Agreement upon the Executive’s death, and the designation may be changed from
time to time by the Executive by filing a new designation. Each designation will revoke all prior designations by the Executive, shall be in the form prescribed by the Administrator, and shall be effective only when filed in writing with the
Administrator during the Executive’s lifetime. If the Executive names someone other than the Executive’s spouse as a Beneficiary, the Administrator may, in its sole discretion, determine that spousal consent is required to be provided in a
form designated by the Administrator, executed by the Executive’s spouse and returned to the Administrator. The Executive’s beneficiary designation shall be deemed automatically revoked if the Beneficiary predeceases the Executive or if
the Executive names a spouse as Beneficiary and the marriage is subsequently dissolved. 
 3.2 Absence of Beneficiary
Designation. In the absence of a valid Beneficiary designation, or if, at the time any benefit payment is due to a Beneficiary, there is no living Beneficiary validly named by the Executive, the Employer shall pay the benefit payment to the
Executive’s spouse. If the spouse is not living, then the Employer shall pay the benefit payment to the Executive’s living descendants per stirpes, and if there are no living descendants, to the Executive’s estate. In
determining the existence or identity of anyone entitled to a benefit payment, the Employer may rely conclusively upon information supplied by the Executive’s personal representative, executor, or administrator. 

ARTICLE 4 

ADMINISTRATION 
 4.1 Administrator Duties. The Administrator shall be responsible for the management, operation, and administration of the Agreement. When making a determination or calculation, the Administrator
shall be entitled to rely on information furnished by the Employer, Executive or Beneficiary. No provision of this Agreement shall be construed as imposing on the Administrator any fiduciary duty under ERISA or other law, or any duty similar to any
fiduciary duty under ERISA or other law. 
 4.2 Administrator Authority. The Administrator shall enforce this Agreement
in accordance with its terms, shall be charged with the general administration of this Agreement, and shall have all powers necessary to accomplish its purposes. 

  
 8 

 4.3 Binding Effect of Decisions. Any decision or action of the Administrator with
respect to any question arising out of or in connection with the administration, interpretation or application of this Agreement and the rules and regulations promulgated hereunder shall be final, conclusive and binding upon all persons having any
interest in this Agreement. 
 4.4 Compensation, Expenses and Indemnity. The Administrator shall serve without
compensation for services rendered hereunder. The Administrator is authorized at the expense of the Employer to employ such legal counsel and/or recordkeeper as it may deem advisable to assist in the performance of its duties hereunder. Expenses and
fees in connection with the administration of this Agreement shall be paid by the Employer. 
 4.5 Employer Information.
The Employer shall supply full and timely information to the Administrator on all matters relating to the Executive’s compensation, death, Disability or Separation from Service, and such other information as the Administrator reasonably
requires. 
 4.6 Termination of Participation. If the Administrator determines in good faith that the Executive no longer
qualifies as a member of a select group of management or highly compensated employees, as determined in accordance with ERISA, the Administrator shall have the right, in its sole discretion, to cease further benefit accruals hereunder. 

4.7 Compliance with Code Section 409A. The Employer and the Executive intend that the Agreement comply with the provisions of
Code Section 409A to prevent the inclusion in gross income of any amounts deferred hereunder in a taxable year prior to the year in which amounts are actually paid to the Executive or Beneficiary. This Agreement shall be construed, administered
and governed in a manner that affects such intent, and the Administrator shall not take any action that would be inconsistent therewith. 
 ARTICLE 5 
 CLAIMS AND REVIEW PROCEDURES 

5.1 Claims Procedure. A Claimant who has not received benefits under this Agreement that he or she believes should be distributed
shall make a claim for such benefits as follows. 
 (a) Initiation – Written Claim. The Claimant
initiates a claim by submitting to the Administrator a written claim for the benefits. If such a claim relates to the contents of a notice received by the Claimant, the claim must be made within sixty (60) days after such notice was received by
the Claimant. All other claims must be made within one hundred eighty (180) days of the date on which the event that caused the claim to arise occurred. The claim must state with particularity the determination desired by the Claimant.

 (b) Timing of Administrator Response. The Administrator shall respond to such Claimant within
ninety (90) days after receiving the claim. If the Administrator determines that special circumstances require additional time for 

  
 9 

 
processing the claim, the Administrator can extend the response period by an additional ninety (90) days by notifying the Claimant in writing, prior to the end of the initial ninety
(90) day period, that an additional period is required. The notice of extension must set forth the special circumstances and the date by which the Administrator expects to render its decision. 

(c) Notice of Decision. If the Administrator denies part or all of the claim, the Administrator shall notify the
Claimant in writing of such denial. The Administrator shall write the notification in a manner calculated to be understood by the Claimant. The notification shall set forth: (i) the specific reasons for the denial; (ii) a reference to the
specific provisions of this Agreement on which the denial is based; (iii) a description of any additional information or material necessary for the Claimant to perfect the claim and an explanation of why it is needed; (iv) an explanation
of this Agreement’s review procedures and the time limits applicable to such procedures; and (v) a statement of the Claimant’s right to bring a civil action under ERISA Section 502(a) following an adverse benefit determination on
review. 
 5.2 Review Procedure. If the Administrator denies part or all of the claim, the Claimant shall have the
opportunity for a full and fair review by the Administrator of the denial as follows. 
 (a) Initiation –
Written Request. To initiate the review, the Claimant, within sixty (60) days after receiving the Administrator’s notice of denial, must file with the Administrator a written request for review. 

(b) Additional Submissions – Information Access. The Claimant shall then have the opportunity to submit
written comments, documents, records and other information relating to the claim. The Administrator shall also provide the Claimant, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information
relevant (as defined in applicable ERISA regulations) to the Claimant’s claim for benefits. 
 (c)
Considerations on Review. In considering the review, the Administrator shall take into account all materials and information the Claimant submits relating to the claim, without regard to whether such information was submitted or considered in
the initial benefit determination. 
 (d) Timing of Administrator Response. The Administrator shall
respond in writing to such Claimant within sixty (60) days after receiving the request for review. If the Administrator determines that special circumstances require additional time for processing the claim, the Administrator can extend the
response period by an additional sixty (60) days by notifying the Claimant in writing, prior to the end of the initial sixty (60) day period, that an additional period is required. The notice of extension must set forth the special
circumstances and the date by which the Administrator expects to render its decision. 
 (e) Notice of
Decision. The Administrator shall notify the Claimant in writing of its decision on review. The Administrator shall write the notification in a manner calculated to be understood by the Claimant. The notification shall set forth: (a) the
specific reasons for the denial; (b) a reference to the specific 

  
 10 

 
provisions of this Agreement on which the denial is based; (c) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all
documents, records and other information relevant (as defined in applicable ERISA regulations) to the Claimant’s claim for benefits; and (d) a statement of the Claimant’s right to bring a civil action under ERISA Section 502(a).

 ARTICLE 6 
 AMENDMENT AND TERMINATION 
 6.1 Agreement Amendment Generally.
Except as provided in Section 6.2, this Agreement may be amended only by a written agreement signed by both the Employer and the Executive. 
 6.2 Amendment to Ensure Proper Characterization of Agreement. Notwithstanding anything in this Agreement to the contrary, the Agreement may be amended by the Employer at any time, if found
necessary in the opinion of the Employer, (i) to ensure that the Agreement is characterized as plan of deferred compensation maintained for a select group of management or highly compensated employees as described under ERISA, (ii) to
conform the Agreement to the requirements of any applicable law, including but not limited to Code Section 409A, 12 C.F.R Part 359 and the Dodd-Frank Wall Street Reform and Consumer Protection Act, or (iii) to comply with the written
instructions of the Employer’s auditors or banking regulators. 
 6.3 Agreement Termination Generally. Except as
provided in Section 6.4, this Agreement may be terminated only by a written agreement signed by the Employer and the Executive. Such termination shall not cause a distribution of benefits under this Agreement. Rather, upon such termination
benefit distributions will be made at the earliest distribution event permitted under Article 2. The amount of the benefit shall be the amount shown in the applicable column on Schedule A for the triggering distribution event for the Plan Year
ending immediately prior to the date of termination of this Agreement, increased by a pro-rated amount relative to the Executive’s service during the partial Plan Year in which the termination of this Agreement occurs, with interest credited on
the unpaid balance at an annual rate equal to the Distribution Rate, compounded monthly. 
 6.4 Effect of Complete
Termination. Notwithstanding anything to the contrary in Section 6.3, and subject to the requirements of Code Section 409A and Treasury Regulation §1.409A-3(j)(4)(ix), at certain times the Employer may completely terminate and
liquidate the Agreement. In the event of a complete termination under subsection (a) or (c) below, the Employer shall pay the Executive the Account Balance shown on Schedule A for the Plan Year ending immediately prior to the date of
termination. Additionally, the benefit amount shall be increased by a pro-rated amount relative to the Executive’s service during the partial Plan Year in which termination takes place. In the event of a complete termination under subsection
(b) below, the Employer shall pay the present value, determined in accordance with subsection (b), of the remaining benefits due to the 

  
 11 

 
Executive or Beneficiary, or, if neither the Executive nor Beneficiary were receiving benefits at the time of the termination, the benefit which would have been due to the Executive if a
Separation from Service had occurred on the date of the termination of the Agreement. Any complete termination of the Agreement shall occur only under the following circumstances and conditions, in each case provided that all of the applicable
requirements of Treasury Regulation §1.409A-3(j)(4)(ix) are satisfied: 
 (a) Corporate Dissolution or
Bankruptcy. The Employer may terminate and liquidate this Agreement within twelve (12) months of a corporate dissolution taxed under Code Section 331, or with the approval of a bankruptcy court pursuant to 11 U.S.C. §503(b)(1)(A),
provided that all benefits paid under the Agreement are included in the Executive’s gross income in the latest of the following years (or, if earlier, the taxable year in which the amount is actually or constructively received): (i) the
calendar year in which the termination occurs; (ii) the calendar year in which the amount is no longer subject to a substantial risk of forfeiture; or (iii) the first calendar year in which the payment is administratively practicable.

 (b) Change in Control. The Employer may terminate and liquidate this Agreement by taking irrevocable
action to terminate and liquidate this Agreement within the thirty (30) days preceding or the twelve (12) months following a Change in Control. This Agreement will then be treated as terminated only if all arrangements sponsored by the
Employer or its successor immediately after the Change in Control which are treated as deferred under a single plan under Treasury Regulation §1.409A-1(c)(2) are terminated and liquidated with respect to each participant who experienced the
Change in Control so that the Executive and any participants in any such similar arrangements are required to receive all amounts of compensation deferred under the terminated arrangements within twelve (12) months of the date the Employer
takes the irrevocable action to terminate the arrangements. If this Agreement is terminated under this subsection (b), the discount rate used to present value the payments will be the Applicable Federal Rate (AFR) based on the timing of the payments
to the Executive, with the first thirty-six (36) months’ payments being discounted at the short-term AFR, the next seventy-two (72) payments (if applicable) discounted at the medium-term AFR and any payments to the Executive over one
hundred eight (108) months in duration being discounted at the long-term AFR. The AFR measurement date will be the month in which the Change in Control occurs. 

(c) Discretionary Termination. The Employer may terminate and liquidate this Agreement provided that: (i) the
termination does not occur proximate to a downturn in the financial health of the Employer; (ii) all arrangements sponsored by the Employer and its Affiliates that would be aggregated with any terminated arrangements under Treasury Regulation
§1.409A-1(c) if the same service provider had deferrals of compensation under such arrangements are also terminated and liquidated; (iii) no payments, other than payments that would be payable under the terms of this Agreement if the
termination had not occurred, are made within twelve (12) months of the date the Employer takes all necessary action to irrevocably terminate and liquidate this 

  
 12 

 
Agreement; (iv) all payments are made within twenty-four (24) months following the date the Employer takes all necessary action to irrevocably terminate and liquidate this Agreement;
and (v) neither the Employer nor any of its Affiliates adopt a new arrangement that would be aggregated with any terminated arrangement under Treasury Regulation §1.409A-1(c) if the same service provider participated in both arrangements,
at any time within three (3) years following the date the Employer takes the irrevocable action to terminate and liquidate this Agreement. 
 ARTICLE 7 
 MISCELLANEOUS 

7.1 No Effect on Other Rights. This Agreement constitutes the entire agreement between the Employer and the Executive as to the
subject matter hereof. No rights are granted to the Executive by virtue of this Agreement other than those specifically set forth herein. Nothing contained herein will confer upon the Executive the right to be retained in the service of the Employer
nor limit the right of the Employer to discharge or otherwise deal with the Executive without regard to the existence hereof. 

7.2 State Law. To the extent not governed by the Code or ERISA, the provisions of this Agreement shall be construed and
interpreted according to the internal law of the Commonwealth of Pennsylvania without regard to its conflicts of laws principles. 
 7.3 Validity. In case any provision of this Agreement shall be illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts hereof, but this Agreement shall
be construed and enforced as if such illegal or invalid provision had never been inserted herein. 
 7.4
Nonassignability. Benefits under this Agreement cannot be sold, transferred, assigned, pledged, attached or encumbered in any manner. 
 7.5 Unsecured General Creditor Status. Payment to the Executive or any Beneficiary hereunder shall be made from assets which shall continue, for all purposes, to be part of the general,
unrestricted assets of the Employer, and no person shall have any interest in any such asset by virtue of any provision of this Agreement. The Employer’s obligation hereunder shall be an unfunded and unsecured promise to pay money in the
future. In the event that the Employer purchases an insurance policy insuring the life of the Executive to recover the cost of providing benefits hereunder, neither the Executive nor the Beneficiary shall have any rights whatsoever in said policy or
the proceeds therefrom pursuant to this Agreement. 
 7.6 Life Insurance. If the Employer chooses to obtain insurance on
the life of the Executive in connection with its obligations under this Agreement, the Executive hereby agrees to take such physical examinations and to truthfully and completely supply such information as may be required by the Employer or the
insurance company designated by the Employer. 

  
 13 

 7.7 Unclaimed Benefits. The Executive shall keep the Employer informed of the
Executive’s current address and the current address of the Beneficiary. If the location of the Executive is not made known to the Employer within three years after the date upon which any payment of any benefits may first be made, the Employer
shall delay payment of the Executive’s benefit payment(s) until the location of the Executive is made known to the Employer; however, the Employer shall only be obligated to hold such benefit payment(s) for the Executive until the expiration of
three (3) years. Upon expiration of the three (3) year period, the Employer may discharge its obligation by payment to the Beneficiary. If the location of the Beneficiary is not made known to the Employer by the end of an additional two
(2) month period following expiration of the three (3) year period, the Employer may discharge its obligation by payment to the Executive’s estate. If there is no estate in existence at such time or if such fact cannot be determined
by the Employer, the Executive and Beneficiary shall thereupon forfeit all rights to any benefits provided under this Agreement. 
 7.8 Suicide or Misstatement. No benefit shall be distributed hereunder if the Executive commits suicide within two (2) years after the Effective Date, or if an insurance company which issued a
life insurance policy covering the Executive and owned by the Employer denies coverage (i) for material misstatements of fact made by the Executive on an application for life insurance, or (ii) for any other reason. 

7.9 Removal. Notwithstanding anything in this Agreement to the contrary, the Employer shall not distribute any benefit under this
Agreement if the Executive is subject to a final removal or prohibition order issued pursuant to Section 8(e) of the Federal Deposit Insurance Act. Furthermore, any payments made to the Executive pursuant to this Agreement shall, if required,
comply with 12 U.S.C. 1828, FDIC Regulation 12 CFR Part 359 and any other regulations or guidance promulgated thereunder. 

7.10 Competition after Separation From Service. 
 7.10.1 Forfeiture Provision. The Executive shall forfeit any non-distributed benefits under this Agreement if, during the period set forth in section 7.10.3 below, the Executive, directly or
indirectly, either as an individual or as a proprietor, stockholder, partner, officer, trustee, employee, agent, consultant or independent contractor of any individual, partnership, corporation or other entity (excluding an ownership interest of
three percent (3%) or less in the stock of a publicly-traded company): 
 (i) becomes employed by,
participates in, or becomes connected in any manner with the ownership, management, operation or control of any bank, savings and loan or other similar financial institution if the Executive’s responsibilities will include providing banking or
other financial services within twenty-five (25) miles of any office maintained by the Employer as of the date of the termination of the Executive’s employment; 

(ii) participates in any way in hiring or otherwise engaging, or assisting any other person or entity in hiring or
otherwise engaging, on a temporary, part-time or permanent basis, any individual who was employed by the Employer as of the date of termination of the Executive’s employment; 

  
 14 

 (iii) assists, advises, or serves in any capacity with, representative or
otherwise, any third party in any action against the Employer or in opposition to any transaction involving the Employer; 
 (iv) sells, offers to sell or provides banking or other financial services, assists any other person in selling or providing banking or other financial services, or solicits or otherwise competes for,
either directly or indirectly, any orders, contracts, or accounts for services of a kind or nature like or substantially similar to the financial services performed or financial products sold by the Employer (the preceding hereinafter referred to as
“Services”), to or from any person or entity from whom the Executive or the Employer, to the knowledge of the Executive, provided banking or other financial services, sold, offered to sell or solicited orders, contracts or accounts for
Services during the three (3) year period immediately prior to the termination of the Executive’s employment; 
 (v) divulges, discloses, or communicates to others in any manner whatsoever, any confidential information of the Employer, to the knowledge of the Executive, including, but not limited to, the names and
addresses of customers or prospective customers of the Employer, as they may have existed from time to time, of work performed or services rendered for any customer, any method and/or procedures relating to projects or other work developed for the
Employer, earnings or other information concerning the Employer. The restrictions contained in this subparagraph (v) apply to all information regarding the Employer, regardless of the source who provided or compiled such information.
Notwithstanding anything to the contrary, all information referred to herein shall not be disclosed unless and until it becomes known to the general public from sources other than the Executive. 

7.10.2 Amendment of Restrictive Covenant. It is expressly understood and agreed that, although the Executive and
the Employer consider the restrictions contained in Section 7.10.1 hereof reasonable for the purpose of preserving for the Employer and its subsidiaries their good will and other proprietary rights, if a final judicial determination is made by
a court having jurisdiction that the time or territory or any other restriction contained in Section 7.10.1 hereof is an unreasonable or otherwise unenforceable restriction against the Executive, the provisions of Section 7.10.1 hereof
shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such other extent as such court may judicially determine or indicate to be reasonable. 

7.10.3 Period of Restrictive Covenant. The provisions of this Section 7.10 shall be applicable commencing on
the date of the Executive’s Separation from Service and continuing for sixty (60) months, provided, however, if there is a Change in Control, the period shall be reduced to twenty-four (24) months and the Executive shall receive
credit for any time that has passed since his Separation from Service. For example, if a Change in Control occurs after the Executive has been Separated from Service for six (6) months, the provisions of this Section 7.10 will only apply
for eighteen (18) additional months. 

  
 15 

 7.11 Notice. Any notice, consent or demand required or permitted to be given to the
Employer or Administrator under this Agreement shall be sufficient if in writing and hand-delivered or sent by registered or certified mail to the Employer’s principal business office. Any notice or filing required or permitted to be given to
the Executive or Beneficiary under this Agreement shall be sufficient if in writing and hand-delivered or sent by registered or certified mail to the last known address of the Executive or Beneficiary, as appropriate. Any notice shall be deemed
given as of the date of delivery or, if delivery is made by mail, as of the date shown on the receipt for registration or certification. 
 7.12 Headings and Interpretation. Headings and sub-headings in this Agreement are inserted for reference and convenience only and shall not be deemed part of this Agreement. Wherever the
fulfillment of the intent and purpose of this Agreement requires and the context will permit, the use of the masculine gender includes the feminine and use of the singular includes the plural. 

7.13 Alternative Action. In the event it becomes impossible for the Employer or the Administrator to perform any act required by
this Agreement due to regulatory or other constraints, the Employer or Administrator may perform such alternative act as most nearly carries out the intent and purpose of this Agreement and is in the best interests of the Employer, provided that
such alternative act does not violate Code Section 409A. 
 7.14 Coordination with Other Benefits. The benefits
provided for the Executive or the Beneficiary under this Agreement are in addition to any other benefits available to the Executive under any other plan or program for employees of the Employer. This Agreement shall supplement and shall not
supersede, modify, or amend any other such plan or program except as may otherwise be expressly provided herein. 
 7.15
Inurement. This Agreement shall be binding upon and shall inure to the benefit of the Employer, its successor and assigns, and the Executive, the Executive’s successors, heirs, executors, administrators, and the Beneficiary. 

7.16 Tax Withholding. The Employer may make such provisions and take such action as it deems necessary or appropriate for the
withholding of any taxes which the Employer is required by any law or regulation to withhold in connection with any benefits under the Agreement. The Executive shall be responsible for the payment of all individual tax liabilities relating to any
benefits paid hereunder. 
 7.17 Aggregation of Agreement. If the Employer offers other non-account balance deferred
compensation plans, this Agreement and those plans shall be treated as a single plan to the extent required under Code Section 409A. 

  
 16 

 IN WITNESS WHEREOF, the Executive and a representative of the Employer have executed this
Agreement as indicated below: 
  

									
	Executive:	 		 	Employer:
				
	 /s/ David Bursic
	 		 	By:	 	 /s/ Keith A. Simpson

	David Bursic	 		 	Title:	 	 Vice President, Treasurer

					
	By:	 	 /s/ David L. Aeberli
	 		 	By:	 	 /s/ Margaret VonDerau

	Title:	 	 Director
	 		 	Title:	 	 Director

					
		 		 		 	By:	 	 /s/ Lawrence M. Lehman

		 		 		 	Title:	 	 Director

					
		 		 		 	By:	 	 /s/ John W. Grace

		 		 		 	Title:	 	 Director

  
 17 

 SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 

Beneficiary Designation 
 I designate the following as Beneficiary under this Agreement: 
 Primary

  

					
		  	 	            	% 
		
		  	 	            	% 

 Contingent 
  

					
		  	 	            	% 
		
		  	 	            	% 

 I understand that I may change this beneficiary designation by delivering a new written designation to
the Administrator, which shall be effective only upon receipt by the Administrator prior to my death. I further understand that the designation will be automatically revoked if the Beneficiary predeceases me or if I have named my spouse as
Beneficiary and our marriage is subsequently dissolved. 
  

											
	Signature:	 	  
	 		 	Date:	 	  
	 	

 SPOUSAL CONSENT (Required only if Administrator requests and someone other than spouse is named Beneficiary) 

I consent to the beneficiary designation above. I also acknowledge that if I am named Beneficiary and my marriage is subsequently dissolved, the
beneficiary designation will be automatically revoked. 
  

											
	Spouse Name:	 	  
	 		 	
						
	Signature:	 	  
	 		 	Date:	 	  
	 	

 Received by the Administrator this      day of
            , 20     
  

			
	By:	 	  

	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]